Combined BRAF and EGFR Inhibition for BRAF V600E–Positive Metastatic Colorectal Cancer and Other Cancers
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Phase Ib/II Trial of BRAF and EGFR inhibition in BRAFV600E metastatic colorectal cancer and other cancers: EVICT (Erlotinib and Vemurafenib In Combination Trial)
Clin. Cancer Res 2023 Jan 13;[EPub Ahead of Print], L Tan, B Tran, J Tie, B Markman, S Ananda, NC Tebbutt, M Michael, E Link, SQ Wong, S Chandrashekar, J Guinto, D Ritchie, R Koldej, BJ Solomon, GA McArthur, RJ Hicks, P Gibbs, SJ Dawson, J DesaiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.